USP30 Inhibitor Compounds for Mitochondrial Dysfunction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective USP30 inhibitors to treat diseases associated with mitochondrial dysfunction, neurodegenerative disorders, and cancer, as current therapies are inadequate in addressing these conditions.
Innovation Solution
Development of specific chemical entities and compounds, represented by Formulas (I), (Ia), and (II), which act as USP30 inhibitors, capable of inhibiting the activity of Ubiquitin Specific Peptidase 30 (USP30), thereby treating diseases related to USP30, including Parkinson's disease and cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If USP30 inhibitors are developed to treat mitochondrial dysfunction and neurodegenerative diseases, then therapeutic effectiveness is improved, but compound complexity and development difficulty increase
Solution Approach 1:
The patent divides the inhibitor compounds into multiple series (Formula I, Formula Ia, Formula II) with distinct structural features, allowing systematic optimization of potency and selectivity while managing overall complexity through modular design approaches
Solution Approach 2:
The patent systematically varies key structural parameters including the R1-R4 substituents, R groups, and n values to optimize the balance between binding affinity to USP30 and pharmacological selectivity, enabling fine-tuning of therapeutic properties without proportionally increasing complexity
2Measurement precision
If USP30 inhibitors are designed with high potency (low IC50 values), then inhibition effectiveness is improved, but synthesis complexity and manufacturing difficulty increase
Solution Approach 1:
The patent establishes preliminary synthetic routes and key intermediate compounds for each formula series, enabling efficient scale-up production while maintaining high potency through pre-optimized structural frameworks
Solution Approach 2:
The patent employs analogues and derivatives within each formula series that replicate the core inhibitory mechanism while simplifying synthesis through shared structural motifs and stepwise modifications
3Adaptability or versatility
If USP30 inhibitors are optimized for selectivity and potency, then therapeutic specificity is improved, but compound structure complexity increases
Solution Approach 1:
The patent introduces specific functional groups and substituents at particular positions (R1-R4, R, n) to achieve localized interactions with USP30 that enhance selectivity and potency without requiring complex overall molecular architecture
Solution Approach 2:
The patent designs a universal core structure across Formula I, Ia, and II that can accommodate multiple therapeutic applications (mitochondrial dysfunction, neurodegenerative diseases, cancer) through systematic variation of substituents, reducing the need for entirely different compound classes
Data Source
AI summary
The present disclosure relates to chemical entities useful as inhibitors of Ubiquitin Specific Peptidase 30 (USP30), pharmaceutical compositions comprising the chemical entities, and methods of using the chemical entities. The chemical entities as disclosed herein can be useful in the treatment of a disease, disorder, or condition involving mitochondrial dysfunction, including neurodegenerative diseases, motor neuron diseases, metabolic disorders, and cancers, among other ailments.